Loading
companiesCompany
Harpoon Therapeutics
Harpoon built small T-cell engager proteins that link a patient's T cells to tumour cells, including HPN328, which targets DLL3 on small cell lung cancer and neuroendocrine tumours. Merck bought the company in early 2024 for about $680 million.
Overview
Harpoon Therapeutics was a South San Francisco clinical-stage company that developed T-cell engagers on its Tri-specific T cell Activating Construct (TriTAC) platform and the ProTriTAC prodrug platform, which keeps the engager inactive until it reaches the tumour. Lead candidate HPN328 is a DLL3-targeting T-cell engager evaluated in patients with small cell lung cancer and neuroendocrine tumours. On 8 January 2024 Merck agreed to acquire Harpoon for $23.00 per share in cash, an approximate total equity value of $680 million, and the merger completed on 11 March 2024, after which Harpoon's Nasdaq listing (HARP) ended. Merck said it would evaluate HPN328 in combinations with its pipeline. The harpoontx.com domain now redirects to merck.com.
Headquarters
South San Francisco, CA, US
Funding
All startupsAcquiredAcquired by Merck & Co. (MSD)
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · $23.00 per share in cash, approximate total equity value $680 million; announced 8 January 2024, completed 11 March 2024 | 2024 | $680M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Website
Notes
top- Former Nasdaq ticker HARP.
Similar pages
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares DLL3, Small-cell lung cancer.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares DLL3, Small-cell lung cancer.
- CompanyJanux Therapeutics
Shares CD3, T-cell engagers (bispecific).
- TrialDeLLphi-305
Shares DLL3, T-cell engagers (bispecific), Small-cell lung cancer.
- TrialStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Shares T-cell engagers (bispecific), Small-cell lung cancer.
- TrialA Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Shares T-cell engagers (bispecific), Small-cell lung cancer.
- PairingSequencing DLL3 engager and B7-H3 ADC in relapsed SCLC
Shares DLL3, Small-cell lung cancer.
- CompanyCytomX Therapeutics
Shares CD3, T-cell engagers (bispecific).